CERO insider transaction filings
CERO THERAPEUTICS HOLDINGS, INC. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-04-21. Screen CERO transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for CERO between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — CERO THERAPEUTICS HOLDINGS, INC.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-04-21 | 4 | Francois Eric — Director | Grant/award (A): 1,823,278 (derivative) @ $0 | EDGAR |
| 2026-01-09 | 4 | Pierce Kristen — Chief Development Officer | Grant/award (A): 1,612,099 (derivative) @ $0 | EDGAR |
| 2026-01-09 | 4 | KUCHARCHUK ANDREW ALBERT — Chief Financial Officer | Grant/award (A): 1,162,099 (derivative) @ $0 | EDGAR |
| 2026-01-09 | 4 | Rolfe Lindsey — Director | Grant/award (A): 690,900 (derivative) @ $0 | EDGAR |
| 2026-01-09 | 4 | Byrnes Michael — Director | Grant/award (A): 690,900 (derivative) @ $0 | EDGAR |
| 2026-01-09 | 4 | Patel Shami — Director | Grant/award (A): 690,900 (derivative) @ $0 | EDGAR |
| 2026-01-09 | 4 | Ehrlich Christopher B — Chairman and CEO, Director | Grant/award (A): 4,530,997 (derivative) @ $0 | EDGAR |
| 2026-01-09 | 4 | ATWOOD BRIAN G — Director | Grant/award (A): 1,612,099 (derivative) @ $0 | EDGAR |
| 2026-01-09 | 4 | LAPORTE KATHLEEN — Director | Grant/award (A): 690,900 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Pierce Kristen — Chief Development Officer | Grant/award (A): 154,841 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | KUCHARCHUK ANDREW ALBERT — Chief Financial Officer | Grant/award (A): 152,500 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Rolfe Lindsey — Director | Grant/award (A): 9,326 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Byrnes Michael — Director | Grant/award (A): 9,326 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Patel Shami — Director | Grant/award (A): 11,693 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Ehrlich Christopher B — Chairman and CEO, Director | Grant/award (A): 61,843 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | ATWOOD BRIAN G — Director | Grant/award (A): 122,549 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | LAPORTE KATHLEEN — Director | Grant/award (A): 9,326 (derivative) @ $0 | EDGAR |
| 2025-04-04 | 4 | ATWOOD BRIAN G — Director | Option exercise (M): 294,460 @ $0.00 · Option exercise (M): 294,460 (derivative) @ $0.00 | EDGAR |
| 2025-03-06 | 4 | Rolfe Lindsey — Director | Grant/award (A): 17,923 (derivative) @ $0 | EDGAR |
| 2025-03-06 | 4 | Byrnes Michael — Director | Grant/award (A): 17,923 (derivative) @ $0 | EDGAR |
| 2025-03-06 | 4 | Patel Shami — Director | Grant/award (A): 14,936 (derivative) @ $0 | EDGAR |
| 2025-03-06 | 4 | Ehrlich Christopher B — Chairman and CEO, Director | Grant/award (A): 119,486 (derivative) @ $0 | EDGAR |
| 2025-03-06 | 4 | ATWOOD BRIAN G — Director | Grant/award (A): 14,936 (derivative) @ $0 | EDGAR |
| 2025-03-06 | 4 | LAPORTE KATHLEEN — Director | Grant/award (A): 17,923 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | Rolfe Lindsey — Director | Grant/award (A): 127,500 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | Byrnes Michael — Director | Grant/award (A): 127,500 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | Patel Shami — Director | Grant/award (A): 127,500 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | Ehrlich Christopher B — Chairman and CEO, Director | Grant/award (A): 1,275,000 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | ATWOOD BRIAN G — Director | Grant/award (A): 254,000 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | LAPORTE KATHLEEN — Director | Grant/award (A): 127,500 (derivative) @ $0 | EDGAR |
| 2025-02-07 | 4 | ATWOOD BRIAN G — Director | Grant/award (A): 306,120 (derivative) @ $0.00 · Grant/award (A): 204,080 (derivative) @ $0.00 · Grant/award (A): 306,120 (derivative) @ $1.96 · Grant/award (A): 204,080 (derivative) @ $1.96 | EDGAR |
| 2024-12-13 | 4 | YK Bioventures Opportunities GP I, LLC — 10% owner YK Bioventures Opportunities Fund I, L.P. — 10% owner Kossar Mitchell William — 10% owner Yeung Gary Kahing — 10% owner | Sale (S): 1,343,801 @ $0.08 · Sale (S): 1,614,541 @ $0.07 · Sale (S): 2,998,908 @ $0.06 | EDGAR |
| 2024-12-10 | 4 | YK Bioventures Opportunities GP I, LLC — 10% owner YK Bioventures Opportunities Fund I, L.P. — 10% owner Kossar Mitchell William — 10% owner Yeung Gary Kahing — 10% owner | Sale (S): 1,236,874 @ $0.12 · Sale (S): 850,543 @ $0.11 · Sale (S): 1,570,947 @ $0.09 | EDGAR |
| 2024-12-04 | 4 | Rolfe Lindsey — Director | Grant/award (A): 127,500 (derivative) @ $0 | EDGAR |
| 2024-12-04 | 4 | Byrnes Michael — Director | Grant/award (A): 127,500 (derivative) @ $0 | EDGAR |
| 2024-12-04 | 4 | Patel Shami — Director | Grant/award (A): 127,500 (derivative) @ $0 | EDGAR |
| 2024-12-04 | 4 | Ehrlich Christopher B — Chairman and CEO, Director | Grant/award (A): 1,275,000 (derivative) @ $0 | EDGAR |
| 2024-12-04 | 4 | ATWOOD BRIAN G — Director | Grant/award (A): 254,000 (derivative) @ $0 | EDGAR |
| 2024-12-04 | 4 | LAPORTE KATHLEEN — Director | Grant/award (A): 127,500 (derivative) @ $0 | EDGAR |
| 2024-11-20 | 4 | SLOAN STUART M — 10% owner | Sale (S): 532,486 @ $0.10 | EDGAR |
| 2024-11-14 | 4 | YK Bioventures Opportunities GP I, LLC — 10% owner YK Bioventures Opportunities Fund I, L.P. — 10% owner Kossar Mitchell William — 10% owner Yeung Gary Kahing — 10% owner | Sale (S): 3,250,000 @ $0.10 | EDGAR |
| 2024-10-02 | 4 | Pierce Kristen — Chief Development Officer | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2024-10-02 | 4 | KUCHARCHUK ANDREW ALBERT — Chief Financial Officer | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2024-10-02 | 4 | Ehrlich Christopher B — Interim Chairman and CEO, Director | Option exercise (M): 5,312,983 · Option exercise (M): 275 (derivative) @ $1,000 · Disposition to issuer (D): 572,182 (derivative) @ $0 | EDGAR |
| 2024-10-02 | 4 | ATWOOD BRIAN G — Director | Option exercise (M): 19,358,578 · Option exercise (M): 1,002 (derivative) @ $1,000 · Disposition to issuer (D): 13,857 (derivative) @ $0 · Disposition to issuer (D): 1,317,956 (derivative) @ $0 | EDGAR |
| 2024-10-02 | 4 | LAPORTE KATHLEEN — Director | Option exercise (M): 965,997 · Option exercise (M): 50 (derivative) @ $1,000 | EDGAR |
| 2024-07-01 | 4 | Carter Charles Ross — Chief Financial Officer | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2024-03-27 | 4 | Ehrlich Christopher B — Director | Grant/award (A): 572,182 (derivative) @ $0 | EDGAR |
| 2024-03-27 | 4 | ATWOOD BRIAN G — Chief Executive Officer, Director | Grant/award (A): 1,317,956 (derivative) @ $0 | EDGAR |
| 2024-03-27 | 4 | LAPORTE KATHLEEN — Director | Grant/award (A): 112,500 (derivative) @ $0 | EDGAR |
Recent 8-K events — CERO THERAPEUTICS HOLDINGS, INC.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-31 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-17 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-26 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-29 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-01 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-14 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-11 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-13 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 4.01 — Changes in Registrant's Certifying Accountant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-04 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-03 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CERO returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →